Description
LIMA1 Antibody | 8053 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human
Homology: Predicted species reactivity based on immunogen sequence: Mouse: (89%) , Pig: (72%)
Immunogen: LIMA1 antibody was raised against an 18 amino acid peptide near the amino terminus of human LIMA1.
The immunogen is located within amino acids 230 - 280 of LIMA1.
Research Area: Cancer, Homeostasis
Tested Application: E, WB, IHC-P, IF
Application: LIMA1 antibody can be used for detection of LIMA1 by Western blot at 0.5 - 1 μg/ml. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Specificiy: LIMA1 antibody is human specific. At least four isoforms of LIMA1 are known to exist; this antibody will only detect the three largest isoforms.
Positive Control 1: Cat. No. 1320 - Human Colon Tissue Lysate
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Predicted: 50, 66, 84 kDa
Observed: 65 kDa
Validation: N/A
Isoform: N/A
Purification: LIMA1 antibody is affinity chromatography purified via peptide column.
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: LIMA1 antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Condition: LIMA1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
Alternate Name: LIM domain and actin-binding protein 1, PP624, EPLIN, SREBP3
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: The Lim domain and actin-binding protein 1 (LIMA1) is cytoskeleton-associated protein that inhibits actin filament depolymerization and cross-links filaments in bundles and is downregulated in some cancer cell lines (1, 2) . LIMA1 is also a key molecule linking the cadherin-catenin complex to the actin cytoskeleton (3) . Recent studies have shown that EGF activates ERK1/2-dependent phosphorylation, ubiquitination and degradation of LIMA1, leading to increased invasiveness and metastasis of metastatic prostate cancer models (4) .